Exelixis Inc
General ticker "EXEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $10.1B
Exelixis Inc follows the US Stock Market performance with the rate: 44.7%.
Estimated limits based on current volatility of 1.3%: low 33.10$, high 33.94$
Factors to consider:
- US accounted for 89.9% of revenue in the fiscal year ended 2023-12-29
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-29 to 2025-12-28
- 2023-12-29 to 2024-12-28 estimated range: [20.48$, 33.41$]
- 2024-12-28 to 2025-12-28 estimated range: [23.11$, 36.95$]
Financial Metrics affecting the EXEL estimates:
- Positive: 0.10 < Non-GAAP EPS, $ of 0.74
- Positive: 9.05 < Operating profit margin, % of 9.34
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
- Positive: 2.86 < Return on assets ratio (scaled to [-100,100]) of 6.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term EXEL quotes
Long-term EXEL plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-30 | 2023-12-29 |
|---|---|---|---|
| Operating Revenue | $1,434.97MM | $1,611.06MM | $1,830.21MM |
| Operating Expenses | $1,148.30MM | $1,409.58MM | $1,659.32MM |
| Operating Income | $286.67MM | $201.48MM | $170.88MM |
| Non-Operating Income | $7.49MM | $32.87MM | $86.64MM |
| R&D Expense | $693.72MM | $891.81MM | $1,044.07MM |
| Income(Loss) | $294.15MM | $234.35MM | $257.52MM |
| Taxes | $63.09MM | $52.07MM | $49.76MM |
| Profit(Loss) | $231.06MM | $182.28MM | $207.76MM |
| Stockholders Equity | $2,210.61MM | $2,488.43MM | $2,263.91MM |
| Inventory | $27.49MM | $33.30MM | $17.32MM |
| Assets | $2,616.24MM | $3,071.49MM | $2,942.36MM |
| Operating Cash Flow | $400.80MM | $362.61MM | $333.32MM |
| Capital expenditure | $64.22MM | $138.46MM | $162.97MM |
| Investing Cash Flow | $-42.88MM | $-524.41MM | $-26.95MM |
| Financing Cash Flow | $-14.80MM | $0.59MM | $-546.05MM |
| Earnings Per Share* | $0.73 | $0.57 | $0.65 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.